[HTML][HTML] SIOP PNET5 MB trial: history and concept of a molecularly stratified clinical trial of risk-adapted therapies for standard-risk medulloblastoma
M Mynarek, T Milde, L Padovani, GO Janssens… - Cancers, 2021 - mdpi.com
Simple Summary The European trial SIOP PNET5 MB was initiated in 2014 and will remain
open to recruitment until 2022. It is the first European trial using clinical, histological, and …
open to recruitment until 2022. It is the first European trial using clinical, histological, and …
[HTML][HTML] Clinical trials in high-risk medulloblastoma: evolution of the SIOP-Europe HR-MB trial
S Bailey, N André, L Gandola, M Massimino… - Cancers, 2022 - mdpi.com
Simple Summary Patients with medulloblastoma receive treatment according to a risk
stratification, which is a combination of clinical and biological factors. To date there have …
stratification, which is a combination of clinical and biological factors. To date there have …
[HTML][HTML] Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT …
M Mynarek, D Obrecht, M Sill, D Sturm… - Acta …, 2023 - Springer
Molecular groups of medulloblastoma (MB) are well established. Novel risk stratification
parameters include Group 3/4 (non-WNT/non-SHH) methylation subgroups I–VIII or whole …
parameters include Group 3/4 (non-WNT/non-SHH) methylation subgroups I–VIII or whole …
[HTML][HTML] Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification
J Goddard, J Castle, E Southworth, A Fletcher… - Acta …, 2023 - Springer
Abstract Group 4 tumours (MBGrp4) represent the majority of non-WNT/non-SHH
medulloblastomas. Their clinical course is poorly predicted by current risk-factors. MBGrp4 …
medulloblastomas. Their clinical course is poorly predicted by current risk-factors. MBGrp4 …
How can genomic innovations in pediatric brain tumors transform outcomes in low-and middle-income countries?
S Bailey, A Davidson, J Parkes, U Tabori… - JCO Global …, 2022 - ascopubs.org
Advances in molecular diagnostics have led to improved stratification and targeted
interventions in the treatment of children with brain tumors. This has necessitated complex …
interventions in the treatment of children with brain tumors. This has necessitated complex …
[HTML][HTML] Genetic alterations of TP53 and OTX2 indicate increased risk of relapse in WNT medulloblastomas
T Goschzik, M Mynarek, E Doerner, A Schenk… - Acta …, 2022 - Springer
This study aimed to re-evaluate the prognostic impact of TP53 mutations and to identify
specific chromosomal aberrations as possible prognostic markers in WNT-activated …
specific chromosomal aberrations as possible prognostic markers in WNT-activated …
Information theory approaches to improve glioma diagnostic workflows in surgical neuropathology
L Cevik, MV Landrove, MT Aslan, V Khammad… - Brain …, 2022 - Wiley Online Library
Aims Resource‐strained healthcare ecosystems often struggle with the adoption of the
World Health Organization (WHO) recommendations for the classification of central nervous …
World Health Organization (WHO) recommendations for the classification of central nervous …
[HTML][HTML] Metabolite profiles of medulloblastoma for rapid and non-invasive detection of molecular disease groups
Background The malignant childhood brain tumour, medulloblastoma, is classified clinically
into molecular groups which guide therapy. DNA-methylation profiling is the current …
into molecular groups which guide therapy. DNA-methylation profiling is the current …
[图书][B] Transforming cancer molecular diagnostics: Molecular subgrouping of medulloblastoma via lowdepth whole genome bisulfite sequencing
D Thompson - 2022 - search.proquest.com
INTRODUCTION: International consensus recognises four molecular subgroups of
medulloblastoma, each with distinct molecular features and clinical outcomes. Assigning …
medulloblastoma, each with distinct molecular features and clinical outcomes. Assigning …